Literature DB >> 15817702

Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction.

Fabrizio Giuliani1, Walter Hader, V Wee Yong.   

Abstract

Minocycline, a tetracycline with anti-inflammatory properties, has been reported to down-regulate the activity of microglia, whose activation occurs in inflammatory and degenerative diseases of the central nervous system, such as multiple sclerosis and Alzheimer's disease. In these disorders, a T cell component is also evident, and we have demonstrated previously that the interaction of activated T cells with microglia led to the substantial increase in tumor necrosis factor alpha (TNF-alpha) levels. Here, we report that minocycline decreases TNF-alpha levels produced in human T cell-microglia interaction. This effect is mediated by a direct action of minocycline on the activated T cells and on microglia, which resulted in the decreased ability of T cells to contact microglia. In correspondence, minocycline decreased the expression on T cells of the CD40 ligand (CD40L), a key molecule regulating the contact-mediated interaction of T cells with microglia. These results demonstrate that the mechanism of action of minocycline involves not only microglia but also T cells and their subsequent activation of microglia. The capacity of minocycline to down-regulate CD40L on T cells may provide a new means to target the CD40-CD40L pathway, which regulates several inflammatory processes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15817702     DOI: 10.1189/jlb.0804477

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  67 in total

1.  The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief.

Authors:  Jenny L Wilkerson; Erin D Milligan
Journal:  ISRN Anesthesiol       Date:  2011

2.  Minocycline suppresses activation of nuclear factor of activated T cells 1 (NFAT1) in human CD4+ T cells.

Authors:  Gregory L Szeto; Joel L Pomerantz; David R M Graham; Janice E Clements
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

Review 3.  GPR18 in microglia: implications for the CNS and endocannabinoid system signalling.

Authors:  D McHugh
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 4.  The multifaceted profile of activated microglia.

Authors:  Marina A Lynch
Journal:  Mol Neurobiol       Date:  2009-07-23       Impact factor: 5.590

5.  Minocycline attenuates HIV-1 infection and suppresses chronic immune activation in humanized NOD/LtsZ-scidIL-2Rγ(null) mice.

Authors:  Maneesh Singh; Pratibha Singh; Dolores Vaira; Mathieu Amand; Souad Rahmouni; Michel Moutschen
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

Review 6.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 7.  Parkinson's disease and enhanced inflammatory response.

Authors:  Iva Stojkovska; Brandon M Wagner; Brad E Morrison
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-13

8.  Impact of different antimycotics on cytokine levels in an in vitro aspergillosis model in human whole blood.

Authors:  Zoe Oesterreicher; Sabine Eberl; Markus Zeitlinger
Journal:  Infection       Date:  2019-08-01       Impact factor: 3.553

9.  Oligomeric Aβ-induced microglial activation is possibly mediated by NADPH oxidase.

Authors:  Juan Li; Jing Yu Yang; Xue Chun Yao; Xue Xue; Qing Chun Zhang; Xiao Xiao Wang; Ling Ling Ding; Chun Fu Wu
Journal:  Neurochem Res       Date:  2012-12-11       Impact factor: 3.996

10.  Brief, low frequency stimulation of rat peripheral C-fibres evokes prolonged microglial-induced central sensitization in adults but not in neonates.

Authors:  Gareth J Hathway; David Vega-Avelaira; Andrew Moss; Rachel Ingram; Maria Fitzgerald
Journal:  Pain       Date:  2009-05-01       Impact factor: 6.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.